Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03212794 · ClinicalTrials.gov registry record · NA

Initiating Substance Use Disorder Treatment for Hospitalized Opioid Use Disorder Patients.

A NA study of Opioid Use Disorder, sponsored by Brigham and Women's Hospital.

Completed
Registry status
NA
Development phase
29
Enrollment target
1
Study location

NCT03212794 is a NA study of Opioid Use Disorder that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 29 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03212794, a NA study of Opioid Use Disorder, has completed, sponsored by Brigham and Women's Hospital.

COMPLETED
Registry status
NA
Development phase
29 participants
Enrollment target
1
Study location

Study Summary

The purpose of this 24-week study is to evaluate the impact of recovery coach intervention on rates of treatment retention, illicit opioid use, and readmission among hospitalized patients newly initiated on buprenorphine or methadone compared to the control intervention.

Conditions Studied

Interventions

  • BEHAVIORAL Recovery coach

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2019-02-11
Est. Completion 2021-12-30
Phase NA

Sponsor

Brigham and Women's Hospital

937 total trials

What the Registry Record Tells You About NCT03212794

The ClinicalTrials.gov registry entry for NCT03212794 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Recovery coach is the first listed.

NCT03212794 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03212794 about?

NCT03212794 is a clinical study titled "Initiating Substance Use Disorder Treatment for Hospitalized Opioid Use Disorder Patients.". The purpose of this 24-week study is to evaluate the impact of recovery coach intervention on rates of treatment retention, illicit opioid use, and readmission among hospitalized patients newly initiated on buprenorphine or methadone compared to the control intervention.

What is the current status of trial NCT03212794?

This trial is currently completed. It is a NA study. The enrollment target is 29 participants. The study started on 2019-02-11. Estimated completion is 2021-12-30.

What conditions does trial NCT03212794 study?

This clinical trial studies the following conditions: Opioid Use Disorder.

What interventions are being tested in trial NCT03212794?

The interventions under investigation include: Recovery coach (BEHAVIORAL).

Who is sponsoring clinical trial NCT03212794?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03212794 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.